The Mouse SARS-CoV-2 IgG1 & IgG2a ELISA kit developed by Creative Diagnostics can help evaluate the type of immune response induced by the COVID-19 vaccine in mouse.
Creative Diagnostics provides a panel of highly sensitive antibiotics ELISA kits to analyze antibiotic residues. These kits are suitable as good impurity detection tools to be used in the bioproduction process.
The Anti-PEG Assay Kits manufactured by Creative Diagnostics, Inc. allows measurement of the anti-PEG antibodies in species who have absorbed PEGylated drugs or proteins, and are suitable for evaluating the pharmacodynamics of candidate drugs.
Creative Diagnostics has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants which can be used to evaluate the efficacy of the antibodies and vaccination.
Creative Diagnostics has developed anti-MMAE antibodies and paired conjugates that are suitable for ADC ELISA assay development.
CD offers a variety of VSV vectors pseudotyped with SARS-CoV-2 Spike proteins. Different products can be used to express different reporters such as EGFP or luciferase, allowing the tracking of viral entry into host cells by a variety of assays.
The SARS-CoV-2 spike CHO-K1 cell line has been developed by stable transfection with SARS-CoV-2 spike protein expression plasmid. SARS-CoV-2 spike CHO-K1 cell line provides consistent levels of expression of SARS-CoV-2 spike protein in cells surface.
Creative Diagnostics has developed a series of functional grade recombinant chimeric antibodies. These antibodies are well-validated in comprehensive applications including Agonism, Blocking, Depletion, Neutralization, WB, IP, FC, and IHC. The newly launched antibodies consist of a series of most popular recombinant mouse anti-mouse antibodies ideal for in vivo research in mouse models.
Creative Diagnostics has recently developed several CLDN18.2 antibodies. The antibodies were validated and characterized by multiple applications with high specificity and affinity.
Immunogenicity assessments in vaccine trials have focused on measurements of antibody responses to the vaccine. Creative Diagnostics has launched a full series of HPV reporter virus particles for measuring neutralizing anti-HPV antibodies in a pseudovirion-based neutralization assay (PBNA).
With the demand for vaccine development, Creative Diagnostics have developed two ELISA Kits for qualitative detection of SARS-CoV-2 neutralizing antibody in serum and plasma.
Creative Diagnostics has launched a full series of ELISA kits for coronavirus antibody detection, including SARS-CoV-2, SARS-CoV, HCoV 229E, HCoV NL63, HCoV OC43 and HCoV HKU1.
Creative Diagnostics provides a list of high-affinity neutralization NRP1 antibodies for your SARS-CoV-2 Intervention Research.
Multiple SARS-CoV-2 variants (B.1.1.7; 501Y.V2) are circulating globally. Creative Diagnostics has produced a collection of recombinant antigens and lentiviral pseudovirus for these variants.
Creative Diagnostics now can provide SARS-CoV-2 Neutralizing Antibodies. These antibodies can be used as reference antibodies in neutralization assays and may also be used in animal research.
Creative Diagnostics now can provide recombinant SARS-CoV-2 accessory proteins and related antibodies.
Creative Diagnostics has developed a panel of serotype-specific S. pneumoniae CPS antibodies for streptococcus pneumoniae vaccines research.
Creative Diagnostics now can provide PLA2R and THSD7A high expressed stable cell lines, which can be used in PLA2R/TSHD7A autoantibody IFA development. Anti-PLA2R/THSD7A IFA Kit is also available for research use.
In response to the COVID-19 pandemic, Creative Diagnostics is now offering the SARS-CoV-2 nucleoprotein antibody pair for rapid COVID-19 antigen assays to equip healthcare workers for rapid COVID-19 antigen detection. We also offer SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction.
Lentiviral SARS-CoV-2 Pseudovirus